JuHyun Bae | Cancer immunotherapy | Best Researcher Award

Best Researcher Award

JuHyun Bae
Affiliation Kyungpook National University School of Medicine
Country South Korea
Scopus ID 57225046295
Documents 15
Citations 375
h-index 10
Subject Area Cancer Immunotherapy
Event Biotechnology Scientist Awards
ORCID 0000-0002-2025-3772

JuHyun Bae
Kyungpook National University School of Medicine

JuHyun Bae, a researcher affiliated with Kyungpook National University School of Medicine, South Korea. This publication-style profile summarizes publicly available scholarly information, including research metrics, publication output, citation performance, scientific contributions, and subject expertise in Cancer Immunotherapy. The article follows a neutral, Wikipedia-inspired presentation suitable for academic recognition and professional reference.[1]

Abstract

JuHyun Bae has established a research profile focused on Cancer Immunotherapy through peer-reviewed scientific publications indexed in international bibliographic databases. Current publicly available metrics indicate 15 indexed publications, 375 citations, and an h-index of 10, reflecting consistent scientific productivity and measurable scholarly influence. This article summarizes the research profile using an objective academic format appropriate for institutional review and research recognition.[1]

Keywords

Cancer Immunotherapy, Oncology, Immunology, Precision Medicine, Translational Medicine, Biomedical Research, Scientific Publications, Citation Analysis, Biotechnology Scientist Awards, Best Researcher Award.

Introduction

Academic excellence is evaluated through a combination of research quality, publication output, citation performance, innovation, and contributions to scientific advancement. Bibliometric databases such as Scopus provide standardized indicators that assist universities, research organizations, funding agencies, and award committees in conducting objective evaluations while complementing expert peer review.[2]

Research Profile

JuHyun Bae is affiliated with Kyungpook National University School of Medicine in South Korea. The available scholarly record demonstrates active research in Cancer Immunotherapy with publications appearing in internationally indexed journals. The research portfolio contributes to ongoing investigations in biomedical science, translational medicine, and cancer-related therapeutic strategies.[1]

Research Contributions

  • Published peer-reviewed research in Cancer Immunotherapy and biomedical sciences.
  • Supported advances in translational oncology research.
  • Contributed to internationally indexed scientific literature.
  • Participated in collaborative biomedical research activities.
  • Enhanced scientific knowledge through evidence-based medical research.

Publications

The researcher’s Scopus profile records 15 indexed publications. These scholarly works contribute to Cancer Immunotherapy and related biomedical disciplines. Many scientific articles include Digital Object Identifiers (DOIs), providing permanent identification and reliable access to published research while supporting accurate scholarly citation.[3]

  • Peer-reviewed journal publications indexed in Scopus.
  • Research articles in oncology, immunology, and translational medicine.

Research Impact

Bibliometric indicators report 15 indexed documents, 375 citations, and an h-index of 10. These metrics demonstrate measurable scholarly visibility and research influence within the biomedical sciences. Quantitative indicators should be interpreted together with publication quality, originality, scientific rigor, collaborative engagement, and broader contributions to medical research.[1]

Award Suitability

Based on publicly available academic indicators, JuHyun Bae demonstrates characteristics commonly considered during evaluations for recognition programs such as the Biotechnology Scientist Awards. Consideration may include publication quality, research significance, citation influence, innovation, ethical research conduct, collaborative achievements, and contributions to Cancer Immunotherapy. Final award decisions remain subject to independent peer review and committee evaluation.[2]

Conclusion

This academic profile presents a structured overview of JuHyun Bae’s scholarly achievements using publicly available bibliographic information. The article follows a neutral encyclopedia-style presentation that emphasizes research productivity, publication performance, scientific impact, and professional contributions, making it suitable for academic reference, institutional evaluation, and research recognition.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: JuHyun Bae, Author ID 57225046295. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57225046295
  2. Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.
    https://www.sciencedirect.com/science/article/pii/S2452199X26003701?via%3Dihub
  3. Determination of extracellular vesicle size and surface charge density via precise measurements of Brownian motion, electrophoretic velocity, and applied electric field in a single platform.
    https://www.sciencedirect.com/science/article/abs/pii/S0925400526001486?via%3Dihub

Dr. David Bartlett | Surgical Oncology | Best Researcher Award

Dr. David Bartlett | Surgical Oncology | Best Researcher Award

Dr. David Bartlett | Allegheny Health Network | United States

Dr. David L. Bartlett is a distinguished surgical oncologist and cancer researcher specializing in innovative cancer treatments. πŸŽ—οΈ He earned his M.D. from the University of Texas Medical School at Houston and completed his residency at the Hospital of the University of Pennsylvania. πŸ₯ He further honed his expertise through fellowships at Memorial Sloan Kettering Cancer Center. Dr. Bartlett has held prestigious leadership roles at the National Cancer Institute, University of Pittsburgh, and Allegheny Health Network, where he currently serves as System Chair of the AHN Cancer Institute. His contributions to surgical oncology and cancer research have shaped modern treatment approaches. πŸ”¬

Professional Profile:

ORCID

Suitability for Best Researcher Award

Dr. David L. Bartlett is an exceptional candidate for the Best Researcher Award due to his groundbreaking contributions to surgical oncology and cancer research. His extensive experience in oncologic surgery, innovative treatment methods, and leadership in major cancer institutions sets him apart as a leading figure in the field. His work has significantly advanced cancer treatment strategies, improving patient outcomes and shaping the future of oncology.

Education & Experience πŸŽ“πŸ“œ

  • B.A. – Rice University, Houston, Texas (1983) πŸŽ“
  • M.D. – University of Texas Medical School at Houston (1987) 🩺
  • Residency – Surgery, Hospital of the University of Pennsylvania (1987-1993) πŸ₯
  • Fellowship – Surgical Oncology, Memorial Sloan Kettering Cancer Center (1993-1995) πŸ”¬
  • Special Expert – Surgery Branch, National Cancer Institute (1995-1996) 🧬
  • Senior Investigator – National Cancer Institute (1996-2001) πŸ₯
  • Associate Professor – University of Pittsburgh (2001-2005) πŸ“š
  • Chief, Surgical Oncology – University of Pittsburgh (2001-2011) πŸ₯
  • Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) πŸŽ–οΈ
  • System Chair – AHN Cancer Institute (2020-present) 🌍

Professional Development & Leadership πŸ†

Dr. Bartlett has significantly advanced surgical oncology through leadership roles and contributions to professional societies. πŸŽ—οΈ He has been actively involved in the Society of Surgical Oncology (SSO), serving as Vice President, President-Elect, and President. πŸŽ–οΈ His work includes chairing the UPMC Robotic Oversight Committee, leading the Regional Cancer Therapies Annual Meeting, and contributing to the FDA’s Cellular, Tissues, and Gene Therapies Advisory Committee. πŸ₯ As an editorial board member for journals like Cancer Gene Therapy and Clinical Colorectal Cancer, he has influenced research directions. Currently, as System Chair of the AHN Cancer Institute, he continues to pioneer cancer treatment advancements. πŸ”¬

Research Focus πŸ”

Dr. Bartlett specializes in cancer immunotherapy, regional cancer therapies, and surgical oncology. πŸŽ—οΈ His research explores gene and cellular therapies, hyperthermic intraperitoneal chemotherapy (HIPEC), and regional perfusion techniques to enhance cancer treatment. πŸ”¬ His NIH-funded studies have led to groundbreaking approaches in treating peritoneal and advanced-stage malignancies. 🧬 He has played a key role in integrating robotics and precision medicine into oncological surgery. πŸ€– His focus on personalized cancer treatments continues to impact global oncology practices. 🌍 Through his work, he has significantly improved patient outcomes and contributed to the evolution of cancer surgery. πŸ₯

Awards & Honors πŸ…

  • Bernard Fisher Endowed Professor of Surgery – University of Pittsburgh (2006-2020) πŸŽ–οΈ
  • President – Society of Surgical Oncology (2019-2020) πŸ†
  • Vice President – Society of Surgical Oncology (2017-2018) πŸŽ—οΈ
  • Editorial Board Member – Cancer Gene Therapy, Annals of Surgical Oncology πŸ“–
  • Chair – UPMC Robotic Oversight Committee (2010-2014) πŸ€–
  • Treasurer – Society of Surgical Oncology (2014-2017) πŸ’°
  • Board of Directors – James Ewing Foundation (2011-2018) πŸ₯
  • FDA Advisory Committee Member – Cellular, Tissues, and Gene Therapies (2014-present) 🧬

Publication Top Notes:

  • 🧫 Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival (2025) – Cancers πŸ₯
  • πŸ‘οΈ Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection (2025) – Biomedicines πŸ§ͺ
  • 🦠 Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immunotherapy (2024) – Cancers πŸ’Š
  • πŸ₯ Assessing the Long-Term Priorities of Pancreaticoduodenectomy Survivors (2024) – HPB ❀️
  • 🧬 Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models (2024) –CancerπŸ”¬